This educational series is supported by an independent educational grant from: AstraZeneca; Merck; Pfizer Inc.

CME Available: https://auau.auanet.org/node/29200

Course Description: Over the last several years, there has been a dramatic increase in our understanding of the role of genetic testing in prostate cancer. Urologists are suddenly being confronted with new information surrounding screening guidelines for men at high genetic risk of prostate cancer, genetic testing in men with both localized and metastatic prostate cancer, and the impact on treatment decisions in men with prostate cancer and inherited DNA damage repair gene mutations.

To increase urologists understanding related to the newest treatment options for prostate cancer, the featured 60-minute panel discussion led by experts in their field, will explore how to translate the latest scientific advances into routine clinical practice, improving the care of patients who are at a markedly-elevated risk of progressions and death from prostate cancer.

The Genetic Testing in Prostate Cancer: Considerations for Urologists and their Patients Webinar will be recorded and available in webcast format on AUAUniversity and AUA’s YouTube channel. Additionally, the content will be released as an episode on AUA’s podcast. Learners will also be provided with links to access a patient and caregiver video and fact sheet produced by the Urology Care Foundation to increase patient understanding of genetic testing as it relates to prostate cancer, and facilitate enhanced patient – physician communications in regards to treatment options.

Learning Objectives: At the conclusion of the activity, participants will be able to:

1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

2. Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.

3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

4. Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.